OBJECTIVETo investigate the efficacy of pressure reduction by peritoneal catheterization in patients with malignant ascites-induced abdominal compartment syndrome (ACS).

METHODSClinical data of 29 patients with malignant ascites-induced ACS from October 2002 to October 2008 were analyzed retrospectively. Intra-abdominal pressure (IAP) was reduced by peritoneal catheterization. Changes of intra-abdominal pressure and ascites volume were observed during treatment. Clinical signs and urinary volume were monitored.

RESULTSIAP was less than 25 cm H(2)O in 2 cases, 25 to 35 cm H(2)O in 21 cases, more than 35 cm H(2)O in 6 cases. IAP decreased significantly after drainage of 1000 to 1500 ml of ascites, then IAP curve leveled off. With all the ascites drained, IAP maintained at 11 to 12 cm H(2)O and at 6 to 8 cm H(2)O after 24 hours. Blood pressure was stable without significant changes before and after IAP reduction (P>0.05). The breathing rate and heart rate were improved, and 24 h urinary volume increased significantly after IAP reduction (P<0.01).

CONCLUSIONEarly peritoneal catheterization can improve the cardiac, pulmonary, and renal function in malignant ascites-induced ACS.

Adult ; Aged ; Aged, 80 and over ; Ascites ; complications ; etiology ; Catheterization ; Compartment Syndromes ; etiology ; surgery ; Decompression, Surgical ; methods ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome

The therapeutic effect of sustained intravitreal injectable voriconazole microspheres (VCZ-MS) on an experimental endophthalmitis of Aspergillus fumigatus was investigated. VCZ-MS was prepared successfully and its physico-chemical property was also evaluated. Right eyes of albino rabbits were infected with an intravitreal injection of 1 000 CFU x mL(-1) of susceptible Aspergillus fumigatus. All fungal endophthalmitis models were randomly divided into five groups 48 hours later: Group A is control group with no treatment; in group B, vitrectomy was performed combined with intravitreal 3 times injections of 100 microg x 0.1 mL(-1) voriconazole every other day. In group C, D and E, vitrectomy was performed combined with intravitreal injection of 0.5 mg, 1.0 mg and 1.5 mg VCZ-MS respectively. The treatment effect was assessed by slit lamp and indirect ophthalmoscope funduscopy examination, using clinical grading system of inflammation in the anterior chamber and the vitreous opacity. The optical microscopy revealed that microspheres obtained from the experiment design were opaque, discrete and spherical particles with smooth surfaces. The drug content and encapsulation efficiency of microspheres were 29.94% and 73.5%, respectively. Endophthalmitis occurred in all eyes of group A, and rapidly developed to panophthalmitis. The inflammation grade of group B, C, D or E was lower than that of group A (P < 0.05). The grade of vitreous opacity in group C, D, E is lower than group B (P < 0.05). Two eyes in group C developed to panophthalmitis. But in group D and E, all eyes whose inflammation was controlled had no recurrence with vitreous clear. Histopathological examination showed normal structures in the cured eyes, while most uncured eyes were atrophic and with eyeball destroyed. So, it can be safely concluded that the curative effect of intravitreal VCZ-MS is significantly better than that of routine intraocular injection of voriconazole. The optimal dose is the one containing 1.0 mg voriconazole.
Animals ; Antifungal Agents ; administration & dosage ; therapeutic use ; Aspergillosis ; drug therapy ; pathology ; Aspergillus fumigatus ; Delayed-Action Preparations ; Endophthalmitis ; drug therapy ; microbiology ; pathology ; Eye ; microbiology ; pathology ; Female ; Intravitreal Injections ; Lactic Acid ; Male ; Microspheres ; Polyglycolic Acid ; Pyrimidines ; administration & dosage ; therapeutic use ; Rabbits ; Random Allocation ; Triazoles ; administration & dosage ; therapeutic use ; Voriconazole

Objective: To understand the detection rate, epidemic pattern of respiratory syncytial virus (RSV) in hospitalized children with acute lower respiratory tract infection (ALRTI) in China. Methods: From June 2017 to March 2020, a prospective multi-center study on the viral aetiology among hospitalized children with ALRTI was conducted in six pediatrics hospital of North China, Northeast, Northwest, South China, Southeast, and Southwest China. A total of 2 839 hospitalized children with ALRTI were enrolled, and the respiratory specimens were collected from these cases. A multiplex real-time RT-PCR assay were employed to screen the respiratory viruses, and the molecular epidemiological and clinical characteristics of children infected with RSV were analyzed. Results: The positve rate of RSV was 18.6% (528/2 839), and the positive rate of RSV in different regions ranged from 5.5% to 44.3%. The positive rate of RSV in male was higher than that in female (20.2% vs 16.3%), and there was a significant statistically difference between two groups (χ2=6.74, P=0.009). The positive rate of RSV among children under 5 years old was higher than that among children older than 5 years old (22.3% vs 4.5%), and there was a significant statistically difference between two groups (χ2=97.98,P<0.001). The positive rate of RSV among the <6 months age group was higher than that of other age groups (all P<0.05). During January 2018 and December 2019, RSV was detected in almost all through the year, and showed peaks in winter and spring. RSV-positive cases accounted for 17.0% (46/270) among children with severe pneumonia, including 36 cases infected with RSV alone. Conclusion: RSV is an important viral pathogen in children under 5 years old with ALRTI in China. The virus can be detected almost all through the year and reached the peak in winter and spring. RSV could lead to severe pneumonia in children and caused huge threaten to children's health.
Child ; Humans ; Male ; Female ; Infant ; Child, Preschool ; Respiratory Syncytial Virus Infections/epidemiology* ; Child, Hospitalized ; Prospective Studies ; Respiratory Tract Infections/epidemiology* ; Respiratory Syncytial Virus, Human ; China/epidemiology*